This invention comprising in hydroxypropyl starch for preparing empty capsules in alimentary and medical use, and hydroxypropyl starch-based soft capsules. This invention takes water as solvent, mix with propylene epoxide and catalyst for reaction, after washing, drying, hydroxypropyl starch is completed. The MS level of substitution of starch is around 2˜5, gelatinization point between 25˜60° C. After the hydroxypropyl starch is gelatinized by heating in water, a hydroxypropyl starch matrix soft capsule can be prepared. The invention consists in introducing hydroxypropyl by modifying the molecular chain of starch to improve the flexibility and hydrophilicity of starch. Therefore, a hydroxypropyl starch matrix soft capsule capable of preparing a flexible and disintegrating property is provided.

The present invention relates to a capsule shell with two parts, a cap and a body, the two parts engage telescopically with each other, the capsule shell is used for storing solid substances in powder or granular form and shows a minimized leakage rate of powder when the capsule shell is filled with the solid substances in powder form and is closed.

This disclosure relates to the use of an implantable device to deliver biologically active compounds at a controlled rate for an extended period of time and methods of manufactures thereof. The device is biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.

Disclosed are methods of delivering a therapeutic to a target site of a subject comprising administering a lipid capsule to a target site of a subject, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field, at a frequency for a period of time, to the target site of the subject, wherein the alternating electric field releases the therapeutic from lipid capsule at the target site of the subject. Disclosed are methods of increasing target site specific release of a therapeutic agent in a subject comprising administering a lipid capsule to a target site of a subject, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field, at a frequency for a period of time, to the target site of the subject, wherein the alternating electric field releases the therapeutic agent from the lipid capsule at the target site of the subject, thereby increasing the target site specific release of the therapeutic agent. Disclosed are methods of treating comprise administering a lipid capsule to a target site of a subject in need thereof, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field, at a frequency for a period of time, to the target site of the subject in need thereof, wherein the alternating electric field releases the therapeutic agent from the lipid capsule at the target site of the subject in need thereof. Disclosed are methods of killing a cell comprising administering a lipid capsule to a target site, wherein the lipid capsule comprises a therapeutic agent; and applying an alternating electric field for a period of time, to the target site, wherein the alternating electric field releases the therapeutic agent from the lipid capsule at the target site, wherein the target site comprises a cell, wherein the therapeutic kills the cell.

The invention features solid dosage forms of N-1-pyrrolidine-N-5-(3-trifluoromethoxy)phenyl biguanide, or a pharmaceutically acceptable salt thereof, where the solid dosage form includes an enteric coating and uses thereof.

Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula OC(O)X.sub.1.

##STR00001## each of the two axial ligands has the formula OC(O)X.sub.1 wherein each X.sub.1 is independently substituted or unsubstituted phenyl or C(X.sub.2)(X.sub.3)(X.sub.4); each X.sub.2 is independently substituted or unsubstituted phenyl, or substituted or unsubstituted alkyl; each X.sub.3 is independently hydrogen, hydroxyl, alkyl, amino, X.sub.5C(O)R.sub.13 where X.sub.5 is NH or O, and R.sub.13 is C.sub.1-C.sub.18 alkyl, substituted or unsubstituted aryl or C.sub.1-C.sub.18 aralkyl, or OR.sub.14, where R.sub.14 is C.sub.1-C.sub.18 alkyl, substituted or unsubstituted aryl or C.sub.1-C.sub.18 aralkyl, or together with X.sub.4 is (O); and each X.sub.4 is independenly hydrogen or together with X.sub.3 is (O).

Disclosed in certain embodiments is a delayed release softgel capsules comprise a fill material that is encapsulated in a pH dependent shell composition, the pH dependent shell composition including pectin and gellan gum. Also disclosed are methods of preparing any of the delayed release softgel capsules described herein and methods of use thereof.

The present disclosure belongs to the technical field of soft capsules, and particularly relates to a plant soft capsule and a preparation method and application thereof. The plant soft capsule with excellent performance is prepared from carrageenan, starch, a plasticizer and water by controlling the weight-average molecular weight of the carrageenan to be 1.2×10.sup.6 to 2.0×10.sup.6. Compared with a plant soft capsule in the existing technology, the plant soft capsule of the present discourse has lower production cost, and the product quality meets the requirements of gelatin soft capsules; and on the premise of high production efficiency, a low oil leakage rate is achieved, and the rupture time meets United States Pharmacopoeia (USP) standards. The plant soft capsule prepared according to the present disclosure can be filled with an active component as a content and used for preparation of a plurality of drugs, functional food or dietary nutritional supplements.

A method for treating the gastro-intestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

The present invention provides ingestible dosage form articles such as opaque capsules with reduced light transmittance.